Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR4 | P61073 | 2/20 | 0.51 |
| ▸ | DRD4 | P21917 | 8/20 | 0.43 |
| ▸ | DRD3 | P35462 | 8/20 | 0.43 |
| ▸ | DRD2 | P14416 | 4/20 | 0.43 |
| ▸ | NAMPT | P43490 | 6/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.35 |
| ▸ | DRD1 | P21728 | 7/20 | 0.35 |
| ▸ | HTR2C | P28335 | 7/20 | 0.35 |
| ▸ | DRD5 | P21918 | 3/20 | 0.34 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6131602 | 0.85 | CXCR4 (0.53) | CXCR4DRD4DRD3DRD2NAMPT | |
| SCHEMBL4208333 | 0.81 | CXCR4 (0.56) | CXCR4DRD4DRD3DRD2NAMPT | |
| SCHEMBL12507647 | 0.80 | CXCR4 (0.68) | CXCR4DRD4DRD3DRD2NAMPT | |
| SCHEMBL1206510 | 0.78 | CXCR4 (0.54) | CXCR4DRD4DRD3DRD2NAMPT | |
| SCHEMBL4204384 | 0.78 | DRD4 (0.54) | CXCR4DRD4DRD3DRD2NAMPT | |
| SCHEMBL1638431 | 0.78 | CXCR4 (0.52) | CXCR4DRD4DRD3DRD2NAMPT | |
| SCHEMBL6131509 | 0.77 | CXCR4 (0.49) | CXCR4DRD4DRD3DRD2NAMPT | |
| SCHEMBL6131484 | 0.77 | CXCR4 (0.49) | CXCR4DRD4DRD3DRD2NAMPT | |
| SCHEMBL4209786 | 0.77 | CXCR4 (0.67) | CXCR4DRD4DRD3DRD2NAMPT | |
| SCHEMBL1206686 | 0.77 | CXCR4 (0.63) | CXCR4DRD4DRD3DRD2NAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1550657-A1 | AMINE COMPOUNDS AND USE THEREOF | Kureha Chemical Industry Co., Ltd. (JP) | 2005-07-06 | — | — | EP | claimed |
| US-20050165063-A1 | Amine compounds and use thereof | KUREHA CHEMICAL INDUSTRY COMPANY, LIMITED. (JP) | 2005-07-28 | — | — | US | disclosed |
| EP-1550657-A1 | AMINE COMPOUNDS AND USE THEREOF | Kureha Chemical Industry Co., Ltd. (JP) | 2005-07-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050165063-A1 | Amine compounds and use thereof | NR0B2, NR5A2, NR1H4 | CXCR4 90/4885DRD4 957/4885DRD3 469/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.